Is PYXS or MNPR more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Monopar Therapeutics N/A -12.84% -12.57%

Does the media refer more to PYXS or MNPR?

In the previous week, Pyxis Oncology and Pyxis Oncology both had 4 articles in the media. Pyxis Oncology's average media sentiment score of 0.63 beat Monopar Therapeutics' score of 0.47 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PYXS or CADL more profitable?

Candel Therapeutics' return on equity of -60.42% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Candel Therapeutics N/A -60.42% -41.33%

Does the media prefer PYXS or CADL?

In the previous week, Candel Therapeutics had 3 more articles in the media than Pyxis Oncology. MarketBeat recorded 7 mentions for Candel Therapeutics and 4 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.63 beat Candel Therapeutics' score of -0.08 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is PYXS or DRUG more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Bright Minds Biosciences N/A -20.58% -20.25%

Does the media prefer PYXS or DRUG?

In the previous week, Pyxis Oncology had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 4 mentions for Pyxis Oncology and 3 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.68 beat Pyxis Oncology's score of 0.63 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AURA or PYXS more profitable?

Aura Biosciences' return on equity of -78.12% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Pyxis Oncology N/A -135.60% -85.00%

Does the media favor AURA or PYXS?

In the previous week, Aura Biosciences and Aura Biosciences both had 4 articles in the media. Aura Biosciences' average media sentiment score of 0.70 beat Pyxis Oncology's score of 0.63 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pyxis Oncology 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PYXS or IRWD?

In the previous week, Ironwood Pharmaceuticals had 10 more articles in the media than Pyxis Oncology. MarketBeat recorded 14 mentions for Ironwood Pharmaceuticals and 4 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.63 beat Ironwood Pharmaceuticals' score of 0.36 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ironwood Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Pyxis Oncology (PYXS) Competitors

$3.73 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$3.76 +0.03 (+0.80%)

As of 08/7/2026 07:44 PM Eastern

Compare

PYXS vs. MNPR, CADL, DRUG, AURA, and IRWD

Should you buy Pyxis Oncology stock or one of its competitors? MarketBeat compares Pyxis Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pyxis Oncology include Monopar Therapeutics (MNPR), Candel Therapeutics (CADL), Bright Minds Biosciences (DRUG), Aura Biosciences (AURA), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry.

How does Pyxis Oncology compare to Monopar Therapeutics?

Pyxis Oncology (NASDAQ:PYXS) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Monopar Therapeutics has lower revenue, but higher earnings than Pyxis Oncology. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	17.05	-$79.62M	-$1.31	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

Pyxis Oncology presently has a consensus target price of $7.50, suggesting a potential upside of 101.07%. Monopar Therapeutics has a consensus target price of $112.08, suggesting a potential downside of 5.98%. Given Pyxis Oncology's higher probable upside, equities analysts clearly believe Pyxis Oncology is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Monopar Therapeutics' return on equity of -12.84% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Monopar Therapeutics	N/A	-12.84%	-12.57%

In the previous week, Pyxis Oncology and Pyxis Oncology both had 4 articles in the media. Pyxis Oncology's average media sentiment score of 0.63 beat Monopar Therapeutics' score of 0.47 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pyxis Oncology has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Monopar Therapeutics beats Pyxis Oncology on 8 of the 14 factors compared between the two stocks.

How does Pyxis Oncology compare to Candel Therapeutics?

Pyxis Oncology (NASDAQ:PYXS) and Candel Therapeutics (NASDAQ:CADL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Candel Therapeutics' return on equity of -60.42% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Candel Therapeutics	N/A	-60.42%	-41.33%

Pyxis Oncology presently has a consensus price target of $7.50, indicating a potential upside of 101.07%. Candel Therapeutics has a consensus price target of $18.57, indicating a potential upside of 75.37%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, research analysts plainly believe Pyxis Oncology is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Candel Therapeutics had 3 more articles in the media than Pyxis Oncology. MarketBeat recorded 7 mentions for Candel Therapeutics and 4 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.63 beat Candel Therapeutics' score of -0.08 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Pyxis Oncology has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.51, indicating that its stock price is 151% less volatile than the broader market.

Candel Therapeutics has lower revenue, but higher earnings than Pyxis Oncology. Candel Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	17.05	-$79.62M	-$1.31	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Summary

Pyxis Oncology beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Pyxis Oncology compare to Bright Minds Biosciences?

Pyxis Oncology (NASDAQ:PYXS) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Pyxis Oncology presently has a consensus target price of $7.50, suggesting a potential upside of 101.07%. Bright Minds Biosciences has a consensus target price of $143.83, suggesting a potential upside of 81.31%. Given Pyxis Oncology's higher possible upside, equities research analysts plainly believe Pyxis Oncology is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Bright Minds Biosciences' return on equity of -20.58% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Bright Minds Biosciences	N/A	-20.58%	-20.25%

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bright Minds Biosciences has lower revenue, but higher earnings than Pyxis Oncology. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	17.05	-$79.62M	-$1.31	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

In the previous week, Pyxis Oncology had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 4 mentions for Pyxis Oncology and 3 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.68 beat Pyxis Oncology's score of 0.63 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pyxis Oncology has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.27, suggesting that its share price is 627% less volatile than the broader market.

Summary

Bright Minds Biosciences beats Pyxis Oncology on 8 of the 15 factors compared between the two stocks.

How does Pyxis Oncology compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

In the previous week, Aura Biosciences and Aura Biosciences both had 4 articles in the media. Aura Biosciences' average media sentiment score of 0.70 beat Pyxis Oncology's score of 0.63 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pyxis Oncology	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pyxis Oncology has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Pyxis Oncology	$13.86M	17.05	-$79.62M	-$1.31	N/A

Aura Biosciences presently has a consensus target price of $20.50, suggesting a potential upside of 156.57%. Pyxis Oncology has a consensus target price of $7.50, suggesting a potential upside of 101.07%. Given Aura Biosciences' higher possible upside, equities analysts clearly believe Aura Biosciences is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by company insiders. Comparatively, 5.7% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aura Biosciences' return on equity of -78.12% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Pyxis Oncology	N/A	-135.60%	-85.00%

Summary

Pyxis Oncology beats Aura Biosciences on 8 of the 13 factors compared between the two stocks.

How does Pyxis Oncology compare to Ironwood Pharmaceuticals?

Pyxis Oncology (NASDAQ:PYXS) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Pyxis Oncology's net margin of 0.00%. Ironwood Pharmaceuticals' return on equity of -58.38% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%

Ironwood Pharmaceuticals has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	17.05	-$79.62M	-$1.31	N/A
Ironwood Pharmaceuticals	$296.15M	2.38	$24.02M	$0.77	5.61

In the previous week, Ironwood Pharmaceuticals had 10 more articles in the media than Pyxis Oncology. MarketBeat recorded 14 mentions for Ironwood Pharmaceuticals and 4 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.63 beat Ironwood Pharmaceuticals' score of 0.36 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

39.1% of Pyxis Oncology shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pyxis Oncology has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

Pyxis Oncology presently has a consensus price target of $7.50, indicating a potential upside of 101.07%. Ironwood Pharmaceuticals has a consensus price target of $6.23, indicating a potential upside of 44.29%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Pyxis Oncology is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

Summary

Ironwood Pharmaceuticals beats Pyxis Oncology on 10 of the 17 factors compared between the two stocks.

Get Pyxis Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYXS vs. The Competition

Export

Metric	Pyxis Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$236.32M	$3.69B	$7.02B	$13.01B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-2.85	9.02	270.57	25.03
Price / Sales	17.05	1,297.98	599.88	84.35
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	4.34	17.61	11.21	6.43
Net Income	-$79.62M	-$13.25M	$3.45B	$348.10M
7 Day Performance	40.75%	6.24%	4.67%	4.41%
1 Month Performance	41.29%	-3.50%	-1.28%	-1.11%
1 Year Performance	251.89%	61.28%	77.33%	23.99%

Pyxis Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYXS Pyxis Oncology	2.9615 of 5 stars	$3.73 flat	$7.50 +101.1%	+251.9%	$236.30M	$13.86M	N/A	60	Upcoming Earnings
MNPR Monopar Therapeutics	1.2476 of 5 stars	$119.20 +6.8%	$112.08 -6.0%	+244.0%	$796.15M	N/A	N/A	10	News Coverage Upcoming Earnings Analyst Upgrade
CADL Candel Therapeutics	2.5299 of 5 stars	$10.35 +2.8%	$18.57 +79.4%	+75.9%	$757.61M	N/A	N/A	60	News Coverage Upcoming Earnings Analyst Upgrade
DRUG Bright Minds Biosciences	2.5713 of 5 stars	$77.70 +5.3%	$143.83 +85.1%	+104.4%	$754.80M	N/A	N/A	N/A	Upcoming Earnings
AURA Aura Biosciences	2.9659 of 5 stars	$7.16 +1.7%	$20.50 +186.2%	+17.5%	$740.07M	N/A	N/A	50	News Coverage Upcoming Earnings Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYXS) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pyxis Oncology (PYXS) Competitors

PYXS vs. MNPR, CADL, DRUG, AURA, and IRWD

How does Pyxis Oncology compare to Monopar Therapeutics?

Summary

How does Pyxis Oncology compare to Candel Therapeutics?

Summary

How does Pyxis Oncology compare to Bright Minds Biosciences?

Summary

How does Pyxis Oncology compare to Aura Biosciences?

Summary

How does Pyxis Oncology compare to Ironwood Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS vs. The Competition

Pyxis Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pyxis Oncology (PYXS) Competitors

PYXS vs. MNPR, CADL, DRUG, AURA, and IRWD

How does Pyxis Oncology compare to Monopar Therapeutics?

Which has stronger valuation and earnings, PYXS or MNPR?

Do analysts recommend PYXS or MNPR?

Is PYXS or MNPR more profitable?

Does the media refer more to PYXS or MNPR?

Which has more risk & volatility, PYXS or MNPR?

Do institutionals & insiders believe in PYXS or MNPR?

Summary

How does Pyxis Oncology compare to Candel Therapeutics?

Do insiders & institutionals believe in PYXS or CADL?

Is PYXS or CADL more profitable?

Do analysts rate PYXS or CADL?

Does the media prefer PYXS or CADL?

Which has more volatility and risk, PYXS or CADL?

Which has higher valuation and earnings, PYXS or CADL?

Summary

How does Pyxis Oncology compare to Bright Minds Biosciences?

Do analysts recommend PYXS or DRUG?

Is PYXS or DRUG more profitable?

Do insiders and institutionals believe in PYXS or DRUG?

Which has higher earnings and valuation, PYXS or DRUG?

Does the media prefer PYXS or DRUG?

Which has more volatility and risk, PYXS or DRUG?

Summary

How does Pyxis Oncology compare to Aura Biosciences?

Which has more risk and volatility, AURA or PYXS?

Does the media favor AURA or PYXS?

Which has stronger earnings & valuation, AURA or PYXS?

Do analysts rate AURA or PYXS?

Do insiders & institutionals hold more shares of AURA or PYXS?

Is AURA or PYXS more profitable?

Summary

How does Pyxis Oncology compare to Ironwood Pharmaceuticals?

Is PYXS or IRWD more profitable?

Which has stronger earnings & valuation, PYXS or IRWD?

Does the media prefer PYXS or IRWD?

Do insiders and institutionals have more ownership in PYXS or IRWD?

Which has more risk & volatility, PYXS or IRWD?

Do analysts rate PYXS or IRWD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS vs. The Competition

Pyxis Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools